A Haitian national convicted in Florida for orchestrating a $58 million healthcare fraud conspiracy is drawing renewed scrutiny to the federal 340B Drug Pricing Program, with members of Congress calling for increased oversight and reform to prevent similar schemes.
Prosecutors accused Jean Jethro Alexandre and his co-conspirators in 2025 of recruiting fake patients and offering financial kickbacks if they accepted fraudulent prescriptions written primarily for HIV and AIDS medication by nurse practitioners involved in the operation. Alexandre then cashed in through insurance reimbursements for filling the fake prescriptions, using proceeds to purchase a luxury-car collection including a 2024 Mercedes-Benz S-Class, a 2023 Bentley Flying Spur and a Mercedes G-Class AMG, along with a $2.5 million mansion on Florida's southern coast.
What the Left Is Saying
While the case has prompted Republican calls for program changes, progressive voices have urged caution against using one actor's fraud to justify broad restrictions on safety-net programs. Advocates note that the 340B program was created in 1992 to help safety-net providers serve low-income patients and remains a critical source of funding for community health centers serving underserved populations.
Healthcare reform supporters argue that improving oversight does not require dismantling a program that helps fund care for vulnerable patients who might otherwise lack access to expensive medications. They point out that healthcare fraud exists across all federal programs, and that targeted enforcement against bad actors is preferable to programmatic restrictions that could harm legitimate providers serving real patients.
"The 340B program supports hospitals and clinics in underserved communities that rely on these savings to fund services for patients who can't pay," said a spokesperson for Families USA. "Robust fraud enforcement protects the program; broad restrictions would simply transfer resources away from those who need them most."
What the Right Is Saying
Republican lawmakers, many of whom have long criticized what they call inadequate oversight of the 340B program, pointed to Alexandre's case as evidence that structural reforms are needed.
"The 340B program was created with good intentions to help vulnerable and underserved patients access care, but unfortunately it has evolved into a massive, poorly supervised program with weak transparency and accountability safeguards," said Rep. Diana Harshbarger, R-Tenn., a pharmacist by profession, in a statement to Fox News Digital. "Cases like this demonstrate how the current structure can create opportunities for bad actors to exploit deeply discounted drugs, questionable contract pharmacy arrangements and opaque reimbursement practices for personal profit."
Rep. Morgan Griffith, R-Va., who serves on the health subcommittee of the Energy and Commerce Committee, said Alexandre's scheme highlighted ongoing concerns about program integrity.
"Alexandre's blatantly setting up a fraudulent medical clinic and disregarding important safety net programs as well as finite taxpayer dollars shows the need for the Committee to continue its important work in cracking down on harmful schemes like this one," Griffith said. "Although I am supportive of the 340B Drug Pricing Program, this instance of fraud is yet another example of how the program has strayed far from its initial intent and is something my Health Subcommittee will continue to monitor closely."
What the Numbers Show
The Alexandre case represents one of the largest healthcare fraud schemes tied to the 340B program on record. Key figures include $58 million in false claims submitted to Medicare, Medicaid and private insurers through fraudulent prescriptions, primarily for HIV and AIDS medications.
According to court documents, Alexandre used a nonprofit health clinic he secretly co-owned to purchase drugs at discounted rates through the 340B program and had prescriptions filled by pharmacies that provided reimbursements paid by insurers. The arrangement allowed Alexandre and his colleagues to pocket the difference between what they received in insurer reimbursements and what they paid for drugs under the discount program.
The Government Accountability Office has previously noted that while this revenue-generating model is legitimate when used properly, the financial spreads between discounted acquisition costs and insurer reimbursements create inherent risks. Alexandre was sentenced to just under 10 years in prison and will be transferred to Immigration and Customs Enforcement for removal proceedings after serving his sentence, as he is a native and citizen of Haiti barred from reentering the United States without written permission.
The Trump administration has mounted a series of fraud investigations across federal programs including Medicaid and Medicare, framing them as part of a broader effort to root out waste, abuse and improper payments. That enforcement posture intensified in December 2025 shortly after Alexandre was initially indicted.
The Bottom Line
The conviction of Jean Jethro Alexandre has renewed bipartisan attention on the 340B Drug Pricing Program's vulnerability to exploitation. While Republicans are calling for structural reforms including enhanced transparency requirements and accountability safeguards, observers expect congressional hearings examining whether existing oversight mechanisms adequately protect taxpayer dollars.
Watch for potential legislation addressing contract pharmacy arrangements, reimbursement practices and reporting requirements tied to the program. The Alexandre case is likely to feature prominently in those discussions as both sides seek to balance protecting a program that supports safety-net providers while preventing future exploitation by bad actors.